patient's own venous blood

PreclinicalBiologic

CChinese University of Hong Kong

patient's own venous blood is one of 4 biologic programs targeting Pneumothorax. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumothoraxNot yet recruiting

PneumothoraxPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Pneumothorax

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

—2

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 3

Sclerosol

SSciarra

Preclinical

1 4

patient's own venous blood

CChinese University of Hong Kong

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalNot yet recruiting

Pneumothorax

NCT06883188

Clinical

Trials by Indication[1]

Pneumothorax1 trial

A Pilot Randomised Study Comparing the Clinical Efficacy of Stopping Air Leak by Talc Pleurodesis or Autologous Blood Patch Therapy in Secondary Spontaneous Pneumothorax

Not yet recruiting·CChinese University of Hong Kong·Preclinical·NCT06883188·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for patient's own venous blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — patient's own venous blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for patient's own venous blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese University of Hong Kong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CChinese University of Hong Kong

patient's own venous blood

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Pneumothorax1 trial

References

Drug Info

Quick Facts

Related News